Drug intelligence / Profile preview

ciclesonide + levocetirizine + montelukast

Development stage: Preclinical
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral, Inhalation, Intranasal

Overview

A combination therapy consisting of ciclesonide (a corticosteroid), levocetirizine (an antihistamine), and montelukast (a leukotriene receptor antagonist). This combination targets multiple pathways involved in allergic and inflammatory responses. Ciclesonide reduces inflammation in the airways, levocetirizine blocks histamine receptors to reduce allergy symptoms, and montelukast inhibits leukotriene receptors which play a role in both asthma and allergic rhinitis.

Targets

GR (Glucocorticoid receptor)CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on ciclesonide + levocetirizine + montelukast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciclesonide + levocetirizine + montelukast.

Explore the full profile